However, more recently, the immuno-modulatory effects of anti-VEGF therapy have highlighted the intimate relationship between tumour blood vessels and anti-cancer immunity leading to ongoing clinical trials combining VEGF and checkpoint blockade (53). Here, VEGFA is linked to neoplasm.